Consider in pts with recurrent episodes of venous thrombosis [i.e., deep-vein thrombosis (DVT), pulmonary embolism (PE)]. Causes include (1) venous stasis (e.g., pregnancy, immobilization); (2) vasculitis; (3) cancer and myeloproliferative disorders; (4) oral contraceptives; (5) lupus anticoagulantantibody to platelet phospholipid, stimulates coagulation; (6) HIT; (7) deficiencies of endogenous anticoagulant factorsantithrombin III, protein C, protein S; (8) factor V Leidenmutation in factor V (Arg → Glu at position 506) confers resistance to inactivation by protein C, accounts for 25% of cases of recurrent thrombosis; (9) prothrombin gene mutationGlu → Arg at position 20210 results in increased prothrombin levels; accounts for about 6% of thromboses; (10) otherparoxysmal nocturnal hemoglobinuria, dysfibrinogenemias (abnormal fibrinogen).
The approach to the diagnosis of the pt with DVT and/or PE is discussed in Chap. 133. Pulmonary Thromboembolism and Deep-Vein Thrombosis.
Treatment: Thrombotic Disorders Correct underlying disorder whenever possible; long-term warfarin therapy is otherwise indicated. Anticoagulant Agents
In-hospital anticoagulation is usually initiated with heparin for 4-10 days, with subsequent maintenance on warfarin after an overlap of 3 days. Duration of therapy depends on underlying condition; calf DVT with clear precipitating cause, 3 months; proximal or idiopathic DVT or PE, 6-12 months; recurrent idiopathic DVT, 12 months minimum; embolic disease with ongoing risk factor, long term, indefinite. The new oral Xa and thrombin inhibitors are easier to use than warfarin but much more expensive. They are at least comparably effective, have lower bleeding rates, and do not require laboratory monitoring. Reversal agents are in development. Fibrinolytic Agents Tissue plasminogen activators (tPAs) mediate clot lysis by activating plasmin, which degrades fibrin. Currently available versions include streptokinase, urokinase, anistreplase (acylated plasminogen streptokinase activator complex), and three modestly distinct forms of recombinant tPA: alteplase, tenecteplase, and reteplase. Indications include treatment of DVT, with lower incidence of postphlebitic syndrome (chronic venous stasis, skin ulceration) than with heparin therapy; massive PE, arterial embolic occlusion of an extremity, treatment of acute myocardial infarction (MI), unstable angina pectoris. Dosages for fibrinolytic agents: (1) tPAfor acute MI and massive PE (adult >65 kg), 10-mg IV bolus over 1-2 min, then 50 mg IV over 1 h, and 40 mg IV over next 2 h (total dose = 100 mg). tPA is slightly more effective but more expensive than streptokinase for treatment of acute MI. (2) Streptokinasefor acute MI, 1.5 million IU IV over 60 min; or 20,000 IU as a bolus intracoronary (IC) infusion, followed by 2000 IU/min for 60 min IC. For PE or arterial or DVT, 250,000 IU over 30 min, then 100,000 IU/h for 24 h (PE) or 72 h (arterial or DVT). (3) Urokinasefor PE, 4400 IU/kg IV over 10 min, then 4400 (IU/kg)/h IV for 12 h. Fibrinolytic therapy is usually followed by a period of anticoagulant therapy with heparin. Fibrinolytic agents are contraindicated in pts with (1) active internal bleeding; (2) recent (<2-3 months) cerebrovascular accident; (3) intracranial neoplasm, aneurysm, or recent head trauma. Antiplatelet Agents Aspirin inhibits platelet function by blocking the ability of cyclooxygenase (COX-1) to synthesize thromboxane A2. The thienopyridines (ticlopidine and clopidogrel) inhibit ADP-induced platelet aggregation by blocking its receptor (P2Y12). Dipyridamole acts by inhibiting phosphodiesterase, which permits cAMP levels to increase and block activation. Glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists block the integrin receptors on the platelet and prevent platelet aggregation. Three such agents are now in use: abciximab, an Fab antibody fragment that binds to the activated form of GPIIb/IIIa; eptifibatide, a cyclic heptapeptide that includes the KGD tripeptide motif that the GPIIb/IIIa receptor recognizes; and tirofiban, a tyrosine derivative that mimics the KGD motif. Aspirin (160-325 mg/d) plus clopidogrel (400-mg loading dose then 75 mg/d) may be beneficial in lowering incidence of arterial thrombotic events (stroke, MI) in high-risk pts. Antiplatelet agents are useful in preventing strokes, complications from percutaneous coronary interventions, and progression of unstable angina. |
For a more detailed discussion, see Konkle BA: Bleeding and Thrombosis, Chap. 78, p. 400; Konkle BA: Disorders of Platelets and Vessel Wall, Chap. 140, p. 725; Arruda VR, High KA: Coagulation Disorders, Chap. 141, p. 732; Freedman JE, Loscalzo J: Arterial and Venous Thrombosis, Chap. 142, p. 740; and Weitz JI: Antiplatelet, Anticoagulant, and Fibrinolytic Drugs, Chap. 143, p. 745, in HPIM-19. |
Section 6. Hematology and Oncology